The U.S. FDA has granted 510(k) clearance for the Monte Carlo dose calculation algorithm from Accuray, a developer and manufacturer of radiosurgical devices. The announcement was made today as part of the product's launch at the European Society for Therapeutic Radiology and Oncology meeting in Barcelona, Spain.

According to the Sunnyvale, Calif.-based Accuray, the Monte Carlo dose calculation method takes the probability and potential interactions for each individual photon into account when it calculates the dose being delivered by a single photon. The developer believes that the calculation methodology will be used to treat lung tumors.

Accuray reported that the product is now commercially available worldwide.